Establishing secure connection…Loading editor…Preparing document…

Legal MTA Document

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

LEGAL MTA DOCUMENT

This Material Transfer Agreement ("Agreement") is entered into as of Effective Date: , by and between Provider Name: , with principal place of business at ("Provider"), and Recipient Name: , with principal place of business at ("Recipient").

RECITALS

WHEREAS, Provider possesses certain biological materials, data and associated information described below that are valuable for research purposes; and

WHEREAS, Recipient desires to obtain such Materials solely for Recipient's internal research consistent with the terms and restrictions set forth in this Agreement; and

WHEREAS, Provider is willing to provide the Materials to Recipient subject to the terms, conditions and restrictions contained herein.

NOW, THEREFORE, in consideration of the mutual covenants set forth below, the parties agree as follows.

1. DEFINITIONS

1.1 "Materials" means the tangible biological materials, samples, derivatives, and any physical items provided by Provider and specifically described as:

1.2 "Purpose" means Recipient's research use limited to:

1.3 "Confidential Information" means non-public information disclosed in connection with the Materials that is identified as confidential at the time of disclosure or that, by its nature, should reasonably be understood to be confidential.

2. TRANSFER AND DELIVERY

2.1 Provider will deliver the Materials to Recipient in the quantity and format specified:

2.2 Title to the Materials remains with Provider. Risk of loss for physical shipment passes to Recipient upon delivery to Recipient's carrier or designated delivery location.

3. PERMITTED USE; RESTRICTIONS

3.1 Recipient may use the Materials solely for the Purpose and shall not use the Materials for any commercial purpose, diagnostic purpose, human clinical use, or any other purpose not expressly permitted herein without Provider's prior written consent.

3.2 Recipient shall not distribute, transfer, sublicense, or provide the Materials to third parties without Provider's prior written consent. Notwithstanding the foregoing, Recipient may allow its employees and agents to use the Materials to the extent necessary to accomplish the Purpose and only if those persons are bound by confidentiality and use obligations no less restrictive than those in this Agreement.

3.3 Recipient will comply with all applicable laws, regulations, and institutional policies governing handling, containment, and disposal of the Materials. Recipient shall ensure appropriate biosafety level containment and training for personnel handling the Materials.

4. CONFIDENTIALITY AND PUBLICATION

4.1 Each party will protect Confidential Information of the other party with the same degree of care it uses to protect its own confidential information, but in no event less than reasonable care. Recipient shall not disclose Provider's Confidential Information to third parties without Provider's prior written consent.

4.2 Notwithstanding confidentiality obligations, Recipient may publish results of research using the Materials. Recipient agrees to provide Provider with a copy of any proposed manuscript or public disclosure at least days prior to submission to afford Provider the opportunity to comment and to identify any proprietary information or confidential information it believes should be redacted.

5. INTELLECTUAL PROPERTY

5.1 Provider retains all right, title and interest in and to the Materials and any pre-existing intellectual property related thereto. No license under any patent, copyright, trademark, trade secret or other intellectual property right is granted or implied by transfer of the Materials, except as expressly set forth in this Agreement.

5.2 Recipient shall promptly disclose to Provider any inventions or discoveries arising from use of the Materials and shall cooperate in providing information reasonably necessary for Provider to evaluate potential intellectual property rights. Any grants of rights to intellectual property must be in a separate written agreement signed by both parties.

6. INDEMNIFICATION AND LIABILITY

6.1 Recipient shall indemnify, defend and hold harmless Provider and its officers, directors and employees from and against any and all claims, liabilities, losses, damages and expenses (including reasonable attorneys' fees) arising out of Recipient's handling, use, storage, disposal or transfer of the Materials, except to the extent caused by Provider's gross negligence or willful misconduct.

6.2 EXCEPT AS PROVIDED IN SECTION 6.1, THE MATERIALS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND, AND PROVIDER DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT.

7. TERM; TERMINATION; RETURN

7.1 Term. This Agreement commences on the Effective Date and continues until terminated in accordance with this Section.

7.2 Termination for Convenience. Either party may terminate this Agreement for convenience upon days' written notice to the other party.

7.3 Termination for Cause. Either party may terminate for material breach if such breach remains uncured for days after written notice specifying the breach.

7.4 Return or Destruction. Upon expiration or termination, Recipient shall, at Provider's election, return or destroy all remaining Materials and certify in writing within days that such return or destruction has occurred.

8. COMPLIANCE; PERMITS

8.1 Recipient shall obtain and maintain all permits, licenses and approvals required to receive, possess, handle and use the Materials. Recipient shall comply with all applicable laws and institutional policies.

8.2 Recipient represents that it will not use the Materials in any manner that would create a biosecurity risk or otherwise violate applicable export control or biosafety laws.

9. NOTICES

Notices required by this Agreement shall be in writing and delivered to the addresses set forth above or such other address as a party may designate in writing. Notice is effective upon receipt.

10. MISCELLANEOUS

10.1 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of: without regard to conflict of law principles.

10.2 Entire Agreement. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements and understandings, whether written or oral, relating to the Materials.

10.3 Severability. If any provision of this Agreement is held invalid or unenforceable, the remaining provisions shall remain in full force and effect.

10.4 Amendment. No amendment or modification of this Agreement shall be valid unless in writing and signed by authorized representatives of both parties.

10.5 Waiver. No waiver of any breach of any provision of this Agreement shall constitute a waiver of any other breach or of such provision.

10.6 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument.

ADDITIONAL TERMS

Provider Printed Name:

By:

Date:

Recipient Printed Name:

By:

Date:

Enter text✕
Prepare your document for signing right on this page
  • 01 Edit the text and complete the fields
  • 02 Click Sign Now and on the next screen add recipients and signature fields in SignNow
  • 03 Start your free trial to sign and send your doc
Sign Now

What the Legal MTA Document Is and when it applies

A Legal MTA Document (Material Transfer Agreement) is a written contract that governs the transfer of tangible research materials, biological samples, proprietary compounds, or data between parties for a specified purpose. It defines permitted uses, confidentiality obligations, intellectual property rights, publication controls, liability allocation, and liability limitations. MTAs protect providers against unauthorized use and recipients against undisclosed encumbrances; they also allocate responsibility for biosafety, export controls, and third-party claims. Parties commonly execute MTAs before shipping materials and retain the signed agreement for compliance and audit purposes.

Why a clear Legal MTA Document matters

A well-drafted MTA reduces legal and operational risk by setting explicit use limits, IP treatment, and confidentiality terms. It prevents downstream disputes, clarifies publication and data-sharing rights, and enables compliant transfers across institutional and state boundaries while documenting consent and custody of materials.

Why a clear Legal MTA Document matters

Who typically prepares and signs an MTA

Signatories normally include an authorized institutional representative plus the receiving party; technical contacts are named for logistics and compliance coordination.

  • Universities and research labs — Office of Sponsored Research and PIs managing inbound or outbound sample use agreements and tech transfer obligations.
  • Pharmaceutical and biotech companies — Legal and R&D teams controlling proprietary materials, confidentiality, and downstream license rights.
  • Clinical organizations and CROs — Clinical teams and compliance officers ensuring patient-sample handling, consent alignment, and regulatory traceability.

Essential elements to include in a Professional Legal MTA Document

A professional MTA combines clear definitions, scope of use, IP and publication rules, liability allocation, material handling instructions, and termination provisions to reduce ambiguity and enable compliance.

Definitions

Precise definitions for Materials, Provider, Recipient, and Purpose so scope and obligations are unambiguous across institutions and labs.

Permitted Use

Narrowly state permitted experiments, testing limits, and any prohibitions such as commercial use or human subject research without further approvals.

Intellectual Property

Describe ownership of new inventions, background IP, and licensing expectations, and whether recipient must assign improvements to provider.

Confidentiality

Set confidentiality period, handling procedures, permitted disclosures, and requirements for secure storage and destruction of proprietary data/materials.

Liability & Indemnity

Allocate risk for misuse, define insurance expectations, disclaim warranties for material viability, and set limits on consequential damages.

Termination

State termination events, return or destruction obligations on termination, post-termination reporting, and survival clauses for IP and confidentiality.

Information commonly required inside the Legal MTA Document

Provider name: Full legal entity name
Recipient name: Full legal entity name
Material description: Precise sample or dataset ID
Purpose of transfer: Permitted use description
Effective date: MM/DD/YYYY format
Signature blocks: Authorized signer names and dates

Step-by-step: completing a Legal MTA Document

Follow a consistent sequence to reduce delays: identify parties, describe materials, define permitted use, set IP and confidentiality terms, sign, and log the executed agreement.

  • 01
    Gather parties: Confirm full legal names and authorized signees
  • 02
    Describe materials: Include catalog numbers, strains, or dataset IDs
  • 03
    Set restrictions: List prohibited activities and publication rules
  • 04
    Execute and log: Get signatures and store executed copy centrally

How to set up an online MTA workflow

Configure a repeatable digital workflow that routes the draft MTA for institutional review, signatures, and archival storage.

Field Configuration
Document template Use standard MTA template with variable fields
Approval routing Legal → PI → Compliance → Final signer
Signer authentication Email + SMS code or institutional SSO
Archival location Institutional records system or secure cloud

Where to send and file the signed MTA

Deliver executed copies to legal and research administration systems and ensure the materials shipment references the signed MTA.

  • Provider records: Store signed copy in provider contract repository
  • Recipient records: Log executed MTA with recipient compliance team
  • Logistics team: Include MTA ID on packing and shipping documents
  • Regulatory file: Attach to any related IRB or export filings

Digital signing and eSubmission essentials

Choose a platform that supports audit trails, access controls, and secure storage compatible with institutional policies.

  • File formats: PDF, DOCX supported
  • Authentication: Email, SMS, or SSO
  • Audit trail: IP and timestamp recorded

Common MTA timing items and typical deadlines

MTAs often include specific timing milestones for delivery, use, reporting, and termination to support compliance and logistics planning.

Effective Date:

Date parties enter (MM/DD/YYYY) when obligations begin

Material delivery window:

Provider shipping timeline or agreed delivery date

Use period:

Duration allowed for permitted experiments or analyses

Reporting obligations:

Periodic progress reports or usage notifications

Termination notice:

Advance notice required to end the agreement

Common mistakes when preparing a Legal MTA Document

  • Vague material descriptions that fail to identify strain, lot, or dataset identifiers, creating confusion over what was actually transferred.
  • Unclear permitted use language that omits whether commercial development or secondary research is allowed, risking inadvertent infringement.
  • Missing signature authority where individual signers lack institutional delegation, which can invalidate contractual commitments.
  • Failing to address export control or biosafety compliance when materials cross borders, exposing parties to regulatory violations.

Risks and contractual consequences of an incorrect MTA

Breach liability: Monetary damages or indemnity claims
IP disputes: Loss of ownership or licensing conflicts
Regulatory fines: Sanctions for export or biosafety violations
Loss of access: Provider may terminate material access
Reputational harm: Damaged institutional relationships
Injunction risk: Court orders to halt use or distribution

eSignature vendor comparison for executing MTAs (signNow first)

Basic capability and pricing comparisons can inform platform selection for executing and archiving MTAs electronically without implying endorsement.

signNow DocuSign Adobe Sign PandaDoc HelloSign
Starting Price $8/user/mo $15/user/mo $14/user/mo $19/user/mo $15/user/mo
Free Trial 7-day free trial Varies by vendor Varies by vendor Varies by vendor Varies by vendor
Bulk Send Yes Yes Yes Yes No
Audit Trail Yes Yes Yes Yes Yes
HIPAA Compliant Yes Yes Yes No No
Envelope Cap No envelope cap 100 envelopes/user/year Varies Varies Varies

Realistic scenarios where a Legal MTA Document is used

Two common case examples illustrate how MTAs streamline transfers while protecting IP and compliance obligations.

Case Study 1

A university lab requests a proprietary reagent for validation studies and needs an MTA to confirm permitted academic use and publication rights.

  • Provider requires publication notice and IP carve-outs.
  • The executed MTA allowed data sharing while preserving provider ownership and required return or destruction once the validation phase concluded, preventing unauthorized commercial use.

Case Study 2

A biotech company supplies clinical-grade material to a contract research organization for assay development under a limited-use MTA.

  • The parties agreed on indemnity and biosafety responsibilities.
  • The signed MTA defined handling procedures, reporting timelines, and clarified that any improvements were subject to a separate license negotiation, preserving the provider’s commercial options.

Frequently asked questions about the Legal MTA Document

Answers to common execution, enforceability, and compliance questions for MTAs, focusing on U.S. law and institutional practices.


Need help? Contact support

be ready to get more
Join over 28 million airSlate SignNow users
Sign Now
Company
Forms
Pricing
Resources
Knowledge base
Other Products
© 2026 airSlate Inc. All rights reserved.